Gunderson Dettmer represented client Lightspeed Venture Partners as it co-led the $110 million Series A financing of Triana Biomedicines, Inc., a Boston-based biotechnology company that recently launched its molecular glue discovery platform. Triana’s platform aims to generate products that stabilize pre-existing, or create, de novo interactions between two proteins and alter the fate or functionality of a disease target. The new capital invested will enable Triana to identify multiple, rationally designed molecular glue clinical candidates.

In the announcement of the transaction, Lightspeed partner Dr. Shelley Chu said, “We are excited to lead the Series A for Triana, which operates at the compelling and unique intersection of machine learning, structural biophysics, and glue-focused DEL screening.”

The Gunderson deal team was led by Marcia Hatch and Nate Gray and included Gina Marek, Jessica Crabill, and Phoebe Hung.

Companies:
Lightspeed
Triana